Suppliers / Contract Pharmacal

Contract Pharmacal

United States 357 employees Updated 9 July 2026

Contract Pharmacal is a finished-dose manufacturer based in United States. It appears in 31 regulatory filings across 3 regulators, without an active US DMF or CEP on file. Its filings concentrate with US FDA, UZPHARM (UZ) and NPRA (MY). Its GMP standing is certified by NAFDAC (NG). Its most recent recorded inspection, by US FDA, closed on 14 April 2022 as VAI.

0
active US DMFs
0
valid CEPs
3
registered plants 1 with an FDA FEI number
31
filings across 3 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 14 April 2022 VAI US FDA
  • 15 August 2017 NAI US FDA
  • 9 December 2016 NAI US FDA
  • 8 January 2015 NAI US FDA
  • 4 December 2013 VAI US FDA
  • 8 April 2013 NAI US FDA
  • 7 February 2013 VAI US FDA
  • 25 January 2012 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Hauppauge New York, Nigeria Not on file
HAUPPAUGE, NY, United States Not on file
Hauppauge, United States 2427358

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 25 None
UZPHARM (UZ) 5 None
NPRA (MY) 1 None
NAFDAC (NG) None 1

Comparing suppliers?

Choose your molecules and target markets. Contract Pharmacal comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 3 active litigation matters are on record.
  • The most recent inspection outcome was VAI, on 14 April 2022.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates